Medtronic Expands Robotic Surgery Portfolio with $700M Cornerstone Robotics Deal
Event summary
- Medtronic invests $700M for exclusive distribution rights to Cornerstone Robotics' Sentire™ surgical system in select non-U.S. markets.
- Sentire will complement Medtronic's existing Hugo™ robotic-assisted surgery (RAS) system, creating a dual-platform portfolio.
- Hugo RAS system is now used in 35+ countries with procedure growth exceeding market rate by 2x.
- Sentire received CE Mark approval in May 2026 for multiple surgical specialties.
- Medtronic aims to exceed 50,000 global Hugo RAS procedures by fiscal year-end.
The big picture
This partnership positions Medtronic as the only company offering two complementary robotic surgery platforms, addressing varying surgeon preferences and market needs. The deal underscores the strategic importance of portfolio diversification in the rapidly evolving surgical robotics market, where global adoption remains low but represents significant growth potential. With $700M invested, Medtronic is making a substantial bet on expanding access to minimally invasive surgery solutions worldwide.
What we're watching
- Portfolio Integration
- How Medtronic will balance and integrate two distinct robotic platforms within its surgical ecosystem.
- Market Penetration
- Whether the dual-platform strategy can accelerate adoption in markets with single-digit robotic surgery penetration.
- Competitive Response
- How established players like Intuitive Surgical may react to Medtronic's expanded robotic offering.